Try a new search

Format these results:

Searched for:



Total Results:


Correction to: Effects of growth hormone on bone modeling and remodeling in hypophysectomised young female rats: a bone histomorphometric study

Iglesias, Lysette; Yeh, James K; Castro-Magana, Mariano; Aloia, John F
The following corrections are found in the original publication of the article and corrected as below.
PMID: 31352591
ISSN: 1435-5604
CID: 4010362


Accacha, Siham; Reiss, Allison B; Mejia-Corletto, Jorge; Siegart, Nicolle M; Renna, Heather A; Castro-Magana, Mariano; De Leon, Joshua; Kasselman, Lora J
ISSN: 1708-8267
CID: 2678062

Advanced Glycation End Products (AGEs) Cause Pro-atherogenic Changes in Cholesterol Transport: A Possible Mechanism for Cardiovascular Risk in Diabetes [Meeting Abstract]

Gamez, Jose D; Voloshyna, Iryna; Littlefield, Michael J; Castro-Magana, Mariano; Reiss, Allison B
ISSN: 1081-5589
CID: 2677802

Effects of growth hormone on bone modeling and remodeling in hypophysectomized young female rats: a bone histomorphometric study

Iglesias, Lysette; Yeh, James K; Castro-Magana, Mariano; Aloia, John F
Growth hormone (GH) deficiency causes decreased bone mineral density and osteoporosis, predisposing to fractures. We investigated the mechanism of action of GH on bone modeling and remodeling in hypophysectomized (HX) female rats. Thirty female Sprague-Dawley rats at age 2 months were divided into three groups with 10 rats each: control (CON) group, HX group, and HX + GH (3 mg/kg daily s.c.) group, for a 4-week study. Hypophysectomy resulted in cessation of bone growth and decrease in cancellous bone mass. Periosteal bone formation decreased and bone turnover rate of endocortical and trabecular surfaces increased as compared to the CON group. GH administration for 4 weeks restored weight gain and bone growth and mitigated decrease in bone density after hypophysectomy. However, trabecular bone mass in the proximal tibial metaphysis remained lower in group HX + GH than in group CON. Dynamic histomorphometric analysis showed that bone modeling of periosteal bone formation and growth plate elongation was significantly higher in group HX + GH than in group HX. New bone formed beneath the growth plate was predominately woven bone in group CON and group HX + GH. Bone remodeling and modeling-remodeling mixed modes in the endocortical and PTM sites were enhanced by GH administration; both bone formation and resorption activities were significantly higher than in group HX. In conclusion, GH administration to HX rats reactivated modeling activities in modeling predominant sites and increased new bone formation. GH administration also increases remodeling activities in remodeling predominant sites, giving limited net gain in the bone mass.
PMID: 20652717
ISSN: 1435-5604
CID: 2599122

Differential effects of growth hormone and alpha calcidol on trabecular and cortical bones in hypophysectomized rats

Chaudhry, Afshan A; Castro-Magana, Mariano; Aloia, John F; Yeh, James K
Growth hormone (GH) deficiency in children causes severe growth retardation, vitamin D deficiency, and osteopenia. We investigated whether alfacalcidol (1OHD) alone or in combination with GH can improve bone formation. Forty hypophysectomized female rats (HX) at the age of 8 wk were divided into HX, HX + 1OHD (oral 0.25 microg/kg daily), HX+GH (0.666 mg/0.2 mL SC daily) and HX+GH + 1OHD groups for a 4-wk study. Results showed that GH increased body weight, bone area, bone mineral content (BMC), and bone mineral density (BMD), whereas 1OHD only increased BMC and BMD. In cortical bone, GH increased both periosteal and endocortical bone formation resulting in a significant increase in cortical size and area in percentage, whereas 1OHD suppressed endocortical erosion surface per bone surface (ES/BS) without a significant effect on bone formation rate per bone surface (BFR/BS). In trabecular bone, GH mitigated the bone loss by increasing BFR/BS, whereas the 1OHD effect was by suppression of trabecular bone turnover in the HX rats. The combination of GH and 1OHD had no additive effect on increasing trabecular bone mass. In conclusion, GH activates new bone formation and increases bone turnover whereas 1OHD suppresses bone turnover. The combination intervention does not seem to provide any additive benefit.
PMID: 19092717
ISSN: 1530-0447
CID: 2599162

Effects of growth hormone on bone modeling and remodeling in hypophysectomized female rats [Meeting Abstract]

Iglesias, Lysette; Yeh, James K; Castro-Magana, Mariano; Aloia, John F
ISSN: 0301-0163
CID: 2600962

Interaction of Combined Intervention of Parathyroid Hormone and Growth Hormone on Trabecular and Cortical Bone Formation and Resorption in the Hypophysectomized Rats. [Meeting Abstract]

Guevarra, NN; Castro-Magana, M; Liu, XQ; Aloia, JF; Yeh, JK
ISSN: 0884-0431
CID: 2600912

Differential Effects of Growth Hormone and 1 Alfa Calcidol on Cancellous and Cortical Bone in Hypophysectomized Rats. [Meeting Abstract]

Chaudhry, AA; Castro-Magana, M; Liu, XQ; Aloia, JF; Yeh, JK
ISSN: 0884-0431
CID: 2600902

Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment

Angulo, Moris A; Castro-Magana, Mariano; Lamerson, Michele; Arguello, Raul; Accacha, Siham; Khan, Asjad
Short stature is characteristic of children with Prader-Willi syndrome (PWS). While previous studies have demonstrated acceleration of linear height velocity with growth hormone (GH) treatment, the long-term benefit on final adult height (AH) has not been reported. The objective of this study was to compare AH attained in PWS subjects with and without GH treatment. We reviewed the records of 21 children (aged 8.3 +/- 2.7 years) with PWS and confirmed GH deficiency that attained AH after receiving human GH treatment (0.25 +/- 0.06 mg/kg/week) for a period of 7.9 +/- 1.7 years. A group of 39 non-GH-treated adults with matched initial height standard deviation score (SDS) at age 6.8 +/- 1.3 years was used as control. In the GH-treated group the mean initial height and AH-SDS was -1.9 +/- 1.7 and -0.3 +/- 1.2 respectively (P < 0.0001), whereas the mean initial and AH-SDS in the control group was -1.9 +/- 1.3 and -3.1 +/- 1 respectively (P < 0.0001). Scoliosis was seen in 43% and 39% in the GH-treated and control group respectively. Premature adrenarche (PA) was noticed in 57% of GH-treated group. Six subjects in the control group but none of the GH-treated subjects developed type 2 diabetes mellitus. Our data show that administration of GH to children with PWS restores linear growth and final AH without significant adverse effects other than PA. Further studies will be necessary to determine related morbidity and mortality in individuals with PWS that reached final AH with or without GH treatment.
PMID: 17567883
ISSN: 1552-4825
CID: 3486482

Nongerminomatous germ cell tumor of the pineal gland causing gonadotropin-independent precocious puberty in a child with 47, XYY karyotype - A clinical and radiographic case review

Khan, A; Price, D; Castro-Magana, M; Angulo, M; Canas, JA
A 3-year and 11-months-old boy presented with a 9-month history of increasing penile enlargement, pubic hair, deepening of the voice, and rapid growth. The erect penile length was 14 cm, with bilateral testicular volume of 3 mL. Laboratory evaluation revealed suppressed follicle-stimulating hormone and luteinizing hormone, elevated total testosterone (259 ng/dL), elevated alpha feto-protein (AFP 79 ng/mL), rapidly increasing beta-human chorionic gonadotropin (beta-hCG 14-399 mIU/mL) over 2 weeks, and a karyotype revealed 47, XYY. Radiographic evaluation revealed a 1.5-cm mixed solid/cystic mass in the pineal gland. Chemotherapy was initiated to attempt to normalize the tumor markers (AFP and beta-hCG). This is the first report of a nongerminomatous germ cell tumor (NGGCT) in a 47, XYY karyotype male. Tumor markers (hCG and AFP) should be included in the workup of adult males with 47, XYY as they are in children with precocious puberty.
ISSN: 1051-2144
CID: 3488192